This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

FDA Slaps Osiris For Misleading Medical Claims About Stem-Cell Bandage (Update 1)

This story, originally published on Oct.21, has been changed to clarify that Osiris Therapeutics received an "Untitled Letter" from the FDA warning the company that its Grafix and Ovation products were in violation of rules governing the marketing of HCT/P products.

COLUMBIA, Md. (TheStreet) -- The U.S. Food and Drug Administration has told Osiris Therapeutics ((OSIR - Get Report)) to stop making unproven medical claims about its Grafix "stem cell" band-aid healing diabetic foot ulcers, according to a letter sent to the company last month.

The FDA's "Untitled Letter" is dated Sept. 26 but Osiris withheld the information from investors until today. 

Grafix is not an FDA-approved drug or medical device. Grafix is a bandage embedded with unmodified and uncultured cellular tissue derived from human placentas and other growth factors. As such, Osiris believed Grafix fit under the FDA's definition of a human cells, tissue and cellular and tissue-based product, or HCT/P, which means it could be sold without regulatory review as a drug or medical device.

In its letter, however, FDA told Osiris that two of its products -- Ovation and Grafix -- violate rules governing HCT/P products.

Osiris must now submit Grafix for FDA approval, just like any other drug or biologic product. 

Must Read: Catalyst Pharma: Orphan Drug Poseur, Profiteer

The FDA crackdown on HCT/P products, which has also hit MiMedx ((MDXG - Get Report)) recently, puts a major crimp in Osiris' business plan because it can no longer tout Grafix to doctors treating diabetic foot ulcers.

Osiris had been counting on pushing Grafix into the diabetic foot ulcer market as a way to ramp revenue growth. That plan is now on hold.

Osiris will try to use a recently completed study of Grafix in diabetic foot ulcers as the basis for the product's FDA approval. Don't be surprised if FDA has significant issues with the data collected since Osiris designed this study as a marketing tool, not for FDA review.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
MDXG $7.11 0.14%
OSIR $4.76 -4.90%
TSLA $211.26 -5.10%
YHOO $36.91 2.50%
AAPL $92.95 -0.72%


Chart of I:DJI
DOW 17,644.35 -6.91 -0.04%
S&P 500 2,046.63 -4.49 -0.22%
NASDAQ 4,711.8380 -13.8010 -0.29%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs